18 June 2002
Further arguments against including trisialo-Fe2-transferrin in carbohydrate-deficienttransferrin (CDT): a study on male alcoholics and hazardous drinkers.
Torsten Arndt, Aleksander Korzec, Marij Bär, Jürgen KropfMed Sci Monit 2002; 8(6): CR411-418 :: ID: 420816
Abstract
BACKGROUND: We attempted to determine whether including trisialo-Fe2-transferrinin carbohydrate-deficient transferrin (CDT) affects the diagnostic accuracy of CDT as a marker of chronicexcessive alcohol intake.MATERIAL/METHODS: The criterion standard tests for the diagnosis of alcoholismand alcohol intake were the Composite International Diagnostic Interview (CIDI) and the Timeline-Followback(TLFB). The study groups (alcohol intake in each of the last 4 weeks before blood sampling) were comprisedof 56 controls (280 g/week, no alcoholism),63 alcoholics (>280 g/week, alcoholism diagnosis). CDT analysis was performed with %CDTri-TIA, whichincludes about 50% of trisialo-Fe2-transferrin in CDT, and ChronAlcoI.D, which excludes this transferrinisoform from CDT.RESULTS: Depending on the cut-offs for the CDT/transferrin ratio (upper or lower limitof the test-specific borderlines) and on the patient group, the diagnostic sensitivity was 28.1%-72.3%for %CDTri-TIA, as opposed to 50.0%-82.5% for ChronAlcoI.D. The diagnostic accuracy was 62.8%-78.5% for%CDTri-TIA and 71.8%-86.6% for ChronAlcoI.D. The latter test consistently showed higher diagnostic sensitivityand accuracy than %CDTri-TIA. The diagnostic specificity was 85.7%-98.2% for %CDTri-TIA and 91.1%-92.2%for ChronAlcoI.D. The areas under the ROC curve were 0.810%-0.885 for %CDTri-TIA and 0.867%-0.896 forChronAlcoI.D.CONCLUSIONS: The present study and data from the literature indicate that including partsof trisialo-Fe2-transferrin by the %CDTri-TIA test significantly reduces the diagnostic sensitivity andthus accuracy of CDT as a marker of chronic excessive alcohol use.
Keywords: Alcoholism, Case-Control Studies, Predictive Value of Tests, Sensitivity and Specificity, Transferrin
Editorial
01 March 2024 : Editorial
Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-ThalassemiaDOI: 10.12659/MSM.944204
Med Sci Monit 2024; 30:e944204
In Press
21 Feb 2024 : Clinical Research
Potential Value of HSP90α in Prognosis of Triple-Negative Breast CancerMed Sci Monit In Press; DOI: 10.12659/MSM.943049
22 Feb 2024 : Review article
Differentiation of Native Vertebral Osteomyelitis: A Comprehensive Review of Imaging Techniques and Future ...Med Sci Monit In Press; DOI: 10.12659/MSM.943168
23 Feb 2024 : Clinical Research
A Study of 60 Patients with Low Back Pain to Compare Outcomes Following Magnetotherapy, Ultrasound, Laser, ...Med Sci Monit In Press; DOI: 10.12659/MSM.943732
26 Feb 2024 : Clinical Research
Predictive Value of Combined HbA1c and Neutrophil-to-Lymphocyte Ratio for Diabetic Peripheral Neuropathy in...Med Sci Monit In Press; DOI: 10.12659/MSM.942509
Most Viewed Current Articles
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952